Cargando…
Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion
Patients with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease (CVD). Peroxisome proliferator-activated receptors (PPARs) play an important role in the regulation of energy homeostasis. Therefore, we aimed to observe the effects of combined PPARα/γ agonists on T2DM patien...
Autores principales: | WEI, JINRU, TANG, QUAN, LIU, LIJUAN, BIN, JIANBIN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570181/ https://www.ncbi.nlm.nih.gov/pubmed/23408783 http://dx.doi.org/10.3892/etm.2013.891 |
Ejemplares similares
-
The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021) -
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009) -
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013) -
Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
por: Sekulic-Jablanovic, Marijana, et al.
Publicado: (2017) -
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)